Suzetrigine, a Non‐Opioid Small‐Molecule Analgesic: Mechanism of Action, Clinical, and Translational Science

ABSTRACT The discovery and approval of Suzetrigine (VX‐548, Journavx) marks a significant breakthrough in pain management. It is the first non‐opioid analgesic approved since celecoxib in 1998. Suzetrigine selectively blocks voltage‐gated sodium channel Na v 1.8 and acts exclusively on peripheral nociceptors without crossing the blood–brain barrier, providing analgesia while sparing central nervous system side effects such as dependence, addiction, sedation, and respiratory depression. In vitro experiments have demonstrated that Suzetrigine is a state‐dependent inhibitor with nanomolar potency against human Na v 1.8, exhibiting > 31,000‐fold selectivity compared to other subtypes of sodium channels and molecular targets. Suzetrigine is rapidly absorbed following oral administration with peak plasma concentrations ( T max ) in approximately 3 h under fasting conditions and an effective half‐life ( t 1/2 ) of 23.6 h. Suzetrigine is primarily eliminated via hepatic metabolism. Recent phase II and III clinical trials have validated Suzetrigine's efficacy in acute postoperative pain settings, demonstrating statistically significant reductions in pain intensity over 48 h following abdominoplasty and bunionectomy. Additionally, Suzetrigine has shown favorable safety and tolerability in broader acute pain indications and is under continued investigation for the treatment of chronic neuropathic conditions such as diabetic peripheral neuropathy. Pharmacokinetic and pharmacodynamic data support Suzetrigine's rapid oral absorption, state‐dependent Na v 1.8 inhibition, and limited off‐target activity as confirmed by both nonclinical and clinical safety studies. Suzetrigine received approval for use in January 2025 in the United States only. Ongoing trials are exploring novel formulations, long‐term safety, and integration into multimodal regimens for surgical and non‐surgical pain.